Vol. 5 (01) pp. 1816-1821 DOI: 10.21474/IJAR01/2950

RESVERATROL AS AN ALTERNATIVE TO REGULAR BLOOD TRANSFUSION- A NEW FETAL HAEMOGLOBIN INDUCER FROM NATURAL WORLD

, , and
  • Department of Genetics, Institute of Genetic Medicine and Genomic Science. 30A Thakurhat Road. Kolkata- 700128, West Bengal, India.
  • Department of Genetics, Institute of Genetic Engineering. 30 Thakurhat Road. Kolkata- 700128, West Bengal India.
153 Downloads 903 Views
Crossref

Download Full Paper (PDF)

Abstract

Recent molecular studies of fetal hemoglobin (HbF) regulation have shown promise for the development of clinical HbF inducers to be used in patients with β-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF, have been studied at past in β-thalassemia patient with limited success resulted no universally effective agents. Increased production of fetal hemoglobin (HbF) can ameliorate the severity of both β-thalassemia and sickle cell disease (SCD), the major disorders of β-hemoglobin. The defective production of the β-globin molecule in patients with β-thalassemia can be compensated for by an increase in the production of the β-like globin molecule, γ-globin, which pairs together with α-globin chains to form HbF. Here we examined the clinical studies of one HbF inducer Trans-Resveratrol and found Complete Response (52.2%), Partial Response (18.2%) and Non response (15.9%) in patients who, after more than one year of treatment, remained at the different level of transfusion dependency with extended transfusion intervals. The present study is to provide a resource that will be valuable for the design of future studies of HbF inducers in β-thalassemia. According to our knowledge and literature review, probably this could be the first report for resveratrol clinical trial in eastern Indian population.

Keywords

Article Analytics

References

  1. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 1997;30(2):91-113.? (PubMed)
  2. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840.? (PubMed)
  3. Romero-Perez AI, Ibern-Gomez M, Lamuela-Raventos RM, de La Torre-Boronat MC. Piceid, the major resveratrol derivative in grape juices. J Agric Food Chem. 1999;47(4):1533-1536. ?(PubMed)
  4. Siemann EH, Creasey LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic. 1992;43(1):49-52.
  5. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218-220.? (PubMed)
  6. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191-196.? (PubMed)
  7. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management. Cambridge, UK: Cambridge University Press, 2001.
  8. Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol 2004;124:264?74.
  9. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003;17:43?53.
  10. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005;49(5):472-481.? (PubMed)
  11. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36(1):79-87. ?(PubMed)
  12. Lo L, Singer ST. Thalassemia: current approach to an old disease. Pediatr Clin North Am 2002;49:1165?91.
  13. Olivieri NF. Reactivation of fetal hemoglobin in patients with betathalassemia. Semin Hematol 1996;33:24?42.
  14. . Olivieri NF, Rees DC, Ginder GD, Thein SL, Waye JS, Chang L, et al. Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley?s anemia. Ann N Y Acad Sci 1998;850:100?9.
  15. Cao H. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology 2004;9:223?33.
  16. Lo L, Singer ST. Thalassemia: current approach to an old disease. Pediatr Clin North Am 2002;49:1165?91.
  17. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol 2001;38:367?73.
  18. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 1998;7:1655?8.
  19. Wang HX, Ng TB. Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sci 1999;65:2663?77.
  20. Cle`ment MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998;92:996?1002.
  21. Nicoletta Bianchi, Cristina Zuccato, Ilaria Lampronti, Monica Borgatti and Roberto Gambari. Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of β-Thalassemia and Sickle-Cell Anemia. Advance Access Publication 11 December 2007 & eCAM 2009;6(2)141?151.

How to Cite This Article

Anirban Roy Chowdhury, Puspal De, Sudipa Chakravarty and Amit Chakravarty. (2017); RESVERATROL AS AN ALTERNATIVE TO REGULAR BLOOD TRANSFUSION- A NEW FETAL HAEMOGLOBIN INDUCER FROM NATURAL WORLD, Int. J. of Adv. Res., 5 (01), 1816-1821, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/2950

Corresponding Author

Puspal De
Institute of Genetic Engineering
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.